Neuvotion announced that it plans to launch its FDA-cleared NeuStim neurostimulation. technology later this year.
NeuStim provides non-invasive, high-resolution electrical stimulation to muscles for promoting recovery after stroke and spinal cord injury. The company designed NeuStim to electrically stimulate muscles dynamically and with high precision. It supports hand movement recovery after stroke or spinal cord injury (SCI).
Related: Reflow Medical launches next-gen microcatheters
Stamford, Connecticut-based Neuvotion’s system enables clinicians to quickly scan and pinpoint stimulation targets through an innovative touch-screen interface. It eliminates the need for manual electrode removal and replacement.
Stimulation profiles require a quick setup and can be saved for each user through a graphical user interface on a lightweight mobile device. The company said it also continues to develop its AI-guided neuromodulation methods and platform, including its FocalStim system. It has FocalStim under development for precise spinal cord stimulation for improving and accerlerating movement recovery outcomes.
Neuvotion won FDA clearance for the system last year.
“At Neuvotion we are extremely excited to help create new markets and applications for brain-computer interface and brain-body interface technologies,” said Dr. Chad Bouton, Neuvotion founder and CEO. “We are also thrilled about launching NeuStim™ later this year, and our FocalStim™ product that is under development and will be introduced next year.”
Neuvotion said it also intends to enter into the brain-computer interface (BCI) market with minimally invasive technology under development. It hopes to create a full brain-body interface (BBI) system to restore movement and sensation.
